Oxurion Signs Letter of Intent for Acquisition of Biometrics-Focused CRO

Oxurion NV, a Belgian biopharmaceutical company, announced the signing of a letter of intent to acquire a majority stake in a French Contract Research Organization (CRO) specialized in clinical data management and biometric analysis. This move supports Oxurion's strategy to expand its expertise and offerings for pharmaceutical and biotech industries.

The targeted CRO, with 15 years of experience, is known for its comprehensive solutions in clinical data management and regulatory submissions, ensuring compliance with international standards. It boasts a multidisciplinary team and has developed an eCRF platform to optimize clinical trial processes.

Oxurion plans to acquire 70% of the CRO's share capital, valuing the company at €650,000. Although no financing has been secured yet, Oxurion expects to finalize the transaction by June 2025, following due diligence and necessary agreements.